Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

RenovoRx Q3 2026 Results: Net Loss of $3.65M, Loss Widens

RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on its TAMP therapy platform and Phase III TIGeR-PaC trial. As of October 30, 2026, the company reported 48,250,592 shares of common stock outstanding and maintains its status as a smaller reporting and emerging growth company. The filing includes condensed financial statements for the period ending September 30, 2026, highlighting ongoing commercialization efforts for the RenovoCath device.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.10.3
Gross profit0.90.2
Net income-3.6-2.9
EPS (diluted, $ a share)$-0.08$-0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+300.8%
Gross margin82.4%
Operating margin-303.6%
Source

10-Q filed with the SEC, NASDAQ: RNXT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

RenovoRx, Inc.: key numbers

Share price
$0.9549Close, Nov 16
Market cap
$46.1M
Shares outstanding
48.25MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from RenovoRx, Inc.

All →
6:30 AM ET Form 4
Insider Buying

RenovoRx Executive Chairman and CMO Ramtin Agah Buys $46.5K of Stock

Ramtin Agah, Executive Chairman and CMO, bought 50,000 shares of RenovoRx, Inc. at $0.9297 a share, worth $46.5K in total on Nov 16, 2026. Shares held after the trade: 848,460 (+6.3%).

Value
$46.5K
Shares
50,000
Price
$0.9297
Role
Executive Chairman and CMO
Holding change
+6.3%
Trade date
Nov 16, 2026
4:21 PM ET 8-K
Financial Results

RenovoRx Financial Results

RenovoRx reported record third-quarter 2026 revenue exceeding $1 million, representing a four-fold increase year-over-year. The company expanded its active commercial cancer center customer base to 26 and reaffirmed its full-year 2026 revenue guidance of $3.75 million to $4.25 million.

Term
Q3 2026

“We generated record results in the third quarter as revenue exceeded the million-dollar threshold and we continued to deliver on all three of our core priorities.”

Shaun Bagai, Chief Executive Officer of RenovoRx

“Looking ahead, given the strong momentum, we continue to expect full-year 2026 revenue for RenovoCath in the range of $3.75 million to $4.25 million, which would more than triple 2025 revenue at the midpoint.”

Shaun Bagai, Chief Executive Officer of RenovoRx

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.